80.08 -0.06 (-0.07%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 96.08 | 1-year : | 101.56 |
Resists | First : | 82.26 | Second : | 86.95 |
Pivot price | 79.37 | |||
Supports | First : | 74.66 | Second : | 62.12 |
MAs | MA(5) : | 77.93 | MA(20) : | 80.31 |
MA(100) : | 96.42 | MA(250) : | 107.45 | |
MACD | MACD : | -2.2 | Signal : | -2.6 |
%K %D | K(14,3) : | 36 | D(3) : | 25.8 |
RSI | RSI(14): 46.8 | |||
52-week | High : | 138.47 | Low : | 74.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CNMD ] has closed below upper band by 45.3%. Bollinger Bands are 10.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 81.28 - 81.7 | 81.7 - 81.96 |
Low: | 78.56 - 79.1 | 79.1 - 79.45 |
Close: | 79.3 - 80.12 | 80.12 - 80.65 |
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Thu, 28 Mar 2024
Is CONMED (NYSE:CNMD) Using Too Much Debt? - Simply Wall St
Thu, 28 Mar 2024
CONMED Co. (NYSE:CNMD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Thu, 28 Mar 2024
CONMED Co. (NYSE:CNMD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Tue, 26 Mar 2024
3735 Shares in CONMED Co. (NYSE:CNMD) Purchased by Legato Capital Management LLC - Defense World
Tue, 05 Mar 2024
Here's Why You Should Retain CONMED (CNMD) Stock for Now - Nasdaq
Thu, 15 Feb 2024
CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26% - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 31 (M) |
Shares Float | 31 (M) |
Held by Insiders | 0.5 (%) |
Held by Institutions | 119.9 (%) |
Shares Short | 3,960 (K) |
Shares Short P.Month | 4,800 (K) |
EPS | 2.03 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 27.12 |
Profit Margin | 5.1 % |
Operating Margin | 12.2 % |
Return on Assets (ttm) | 3.4 % |
Return on Equity (ttm) | 8.1 % |
Qtrly Rev. Growth | 30.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 40.28 |
EBITDA (p.s.) | 6.42 |
Qtrly Earnings Growth | 21.2 % |
Operating Cash Flow | 125 (M) |
Levered Free Cash Flow | 182 (M) |
PE Ratio | 39.25 |
PEG Ratio | 0.6 |
Price to Book value | 2.95 |
Price to Sales | 1.98 |
Price to Cash Flow | 19.66 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |